glucagon receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
| Property | Value | Notes |
|---|---|---|
| 研究代号 | LY3437943 | 文献中常用的实验标识 |
| 药物类别 | 三重受体激动剂 | 靶向GLP-1、GIP与胰高血糖素受体 |
| 开发状态 | 后期临床研究 | 尚未获批上市 |
| 主要研究人群 | 肥胖与2型糖尿病 | 入组条件依试验方案而定 |
| 常见同义词 | 瑞他鲁肽；LY3437943 | 名称拼写可能因语言和出版物而异 |
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Flower lotus cultivars are used exclusively for ornamental purpose, producing many flowers and the lowest plant height. The seed production of flower lotus is typically poor regarding yield and quality. Flower types differ in the number of petals (single petals, double petals, or multi-petals) and their colours range from single colour in white, yellow, pink, and red to bi-colour, most often of white petals with pink tips or highlights. One example of a flower lotus is Wanlian. Also known as bowl lotus, wanlians are any miniature cultivars of N. nucifera sized between 5 and 8 centimetres (2.0 and 3.1 in). Bowl lotuses come in various colours and numbers of petals, and they bloom longer than other species of lotus. But together with the rhizome, their seeds are often too small or too hard to be edible. The sacred lotus may be crossed with the yellow lotus to produce interspecific hybrids. A few cultivars have been produced with differing appearances.
== Guinea Bissau == Manuel Serifo Nhamadjo – former interim president and former acting president of the National People's Assembly Brigadier-General Umaro Sissoco Embaló – President of Guinea-Bissau, former prime minister and Minister of African Affairs. Adiato Djaló Nandigna – Current Minister of Fisheries; former acting prime minister, former minister of culture, Youth and Sports and former minister of defense, Guinea Bissau Baciro Djá – former prime minister, former Minister of National Defense and former Minister of Youth and Sport, Guinea Bissau Eloïne Barry – communications professional and founder of African Media Agency. France, Guinea Bissau Fatumata Djau Baldé – Current Minister of Public Administration and State Modernization; former minister of foreign affairs, Guinea Bissau Mamadu Saliu Djaló Pires - Former foreign minister of Foreign Affairs. Mamadú Iaia Djaló – Current Minister of Trade and Industry, Guinea Bissau Tiago Djaló Yannick Djaló Alejandro Balde Mama Baldé Manuel Baldé
==== Common causes of chronic wounds ==== Diabetes mellitus – Wound healing impairment in the setting of diabetes is multifactorial. Hyperglycemia, neuropathy, microvascular complications, impaired immune and inflammatory responses, and psychological factors have all been implicated in the formation and propagation of diabetic wounds. Feet are the most common location of diabetic wounds, although any type of wound can be negatively impacted by diabetes. It has been estimated that up to 25% of patients with diabetes mellitus will be affected by non-healing wounds in their lifetime. Venous/Arterial insufficiency – Impaired blood outflow (venous) or inflow (arterial) can both impair wound healing, thereby causing chronic wounds. Much like diabetes, venous/arterial insufficiency most commonly result in chronic wounds of the lower extremities. In chronic venous insufficiency, blood pooling impedes oxygen exchange and creates a chronic pro-inflammatory environment which both promote formation of venous ulcers. Peripheral artery disease, on the other hand, causes wounds due to poor blood inflow and typically affects the most distal extremities (fingers, toes). Immunologic disease – The immune system plays a critical role in the inflammatory process; therefore, any disease of the immune system has the potential to impair the inflammatory phase of wound healing, thereby leading to a chronic wound. Patients suffering from diseases such as rheumatoid arthritis and lupus have been found to have larger wounds and prolonged time to heal when compared to the general population.
In one interpretation of the film's plot, a scientific process supposedly extracts hydrogen from water, then burns the hydrogen to generate power, and leaves only water as a residue, essentially a chemical perpetual motion. The movie never clarifies how the hydrogen is extracted from the water, nor how water is still left over. The character Dr. Shannon makes contradictory statements in the combination of ideas mashed together: one time he says this is accomplished with a laser with millions of degrees, another time he says frequencies of sound and sonoluminescence. In one scene, the movie shows a bubbling container reminiscent of cold fusion electrolytic cells and another reference sustained fusion. A character in the film claims that a glass of water could power Chicago for weeks, but no clear explanation is ever given as to whether this is by simply burning hydrogen released by highly efficient means or through nuclear processes. The film's title is also misleading, since "chain reaction" is related to nuclear fission, not fusion. The film is based on the premise that free energy suppression is real. The main character is told that his discovery is too disruptive: energy would suddenly be cheap, oil would no longer be necessary, oil companies would go bankrupt, and such sudden economic changes would throw society into chaos.
66th Academy Awards (1994): Best Supporting Actor, nomination, for What's Eating Gilbert Grape 77th Academy Awards (2005): Best Actor, nomination, for The Aviator 79th Academy Awards (2007): Best Actor, nomination, for Blood Diamond 86th Academy Awards (2014): Best Picture and Best Actor, nominations, for The Wolf of Wall Street 88th Academy Awards (2016): Best Actor, win, for The Revenant 92nd Academy Awards (2020): Best Actor, nomination, for Once Upon a Time in Hollywood 98th Academy Awards (2026): Best Actor, nomination, for One Battle After Another DiCaprio has won three Golden Globe Awards: Best Actor – Motion Picture Drama for The Aviator and The Revenant and Best Actor – Motion Picture Musical or Comedy for The Wolf of Wall Street, as well as a BAFTA Award and a Screen Actors Guild Award for Best Actor for The Revenant.
Sources: en.wikipedia.org
=== Wound management === Chitosan has the ability to adhere to fibrinogen, which produces increased platelet adhesion, causing clotting of blood and hemostasis. Chitosan may have other properties conducive to wound healing, including antibacterial and antifungal activity, which remain under preliminary research.
=== Enhancement of physical performance === 1-MNA acts as a myokine, supporting the utilization of amino acids for gluconeogenesis in the liver and stimulating lipolysis in adipose tissue, thereby providing energy for muscles. Studies indicate that 1-MNA supplementation improves exercise tolerance and reduces fatigue. After one month of supplementation with 58 mg of 1-MNA, post-COVID-19 patients reported improved distances in a 6-minute walk test (6MWT), with 92% of participants experiencing better outcomes compared to controls. Additional studies highlight 1-MNA's ability to enhance physical performance by stimulating PGI2 release, protecting microcirculation, and ensuring adequate blood flow to muscle tissues. This mechanism may reduce cardiovascular risks associated with physical exertion, particularly in individuals with impaired endothelial response.
== Applications == Due to the unique temperature-dependent phase transition experienced by ELPs, in which they move from a linear state to a spherical aggregate state above their Tt, as well as the ability of ELPs to be easily conjugated with other compounds, these biopolymers hold numerous applications. Some of these applications involve ELP use in protein purification, cancer therapy, and tissue scaffolding.
=== The efficiency of EI === Increasing the electron ionization process is done by increasing the ionization efficiency. In order to achieve higher ionization efficiency there should be an optimized filament current, emission current, and ionizing current. The current supplied to the filament to heat it to incandescent is called the filament current. The emission current is the current measured between the filament and the electron entry slit. The ionizing current is the rate of electron arrival at the trap. It is a direct measure of the number of electrons in the chamber that are available for ionization. The sample ion current (I+) is the measure of the ionization rate. This can be enhanced by manipulation of the ion extraction efficiency (β), the total ionizing cross section (Qi), the effective ionizing path length (L), the concentration of the sample molecules([N]) and the ionizing current (Ie). The equation can be shown as follows:
Sources: en.wikipedia.org
{\displaystyle \left(\mathbf {w} ,{\frac {\partial \mathbf {u} }{\partial t}}\right)=-{\bigl (}\mathbf {w} ,\left(\mathbf {u} \cdot \nabla \right)\mathbf {u} {\bigr )}-\nu \left(\nabla \mathbf {w} :\nabla \mathbf {u} \right)+\left(\mathbf {w} ,\mathbf {f} ^{S}\right)}
=== Electronics === Thermal evaporation has been investigated for the production of organic light-emitting diodes (OLEDs) and organic photovoltaic cells. In organic photovoltaic cells, the purity of the organic semiconductor layers influences the device's energy conversion efficiency and stability.
== Feedback mechanisms == Signal transduction is a mechanism in which the cell responds to a signal from the environment by activating several proteins and enzymes that will give a response to the signal. Feedback mechanism might involve negative and positive feedbacks. In the negative feedback, the pathway is inhibited and the result of the transduction pathway is reduced or limited. In positive feedback, the transduction pathway is promoted and stimulated to produce more products.
Sources: en.wikipedia.org
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。
司美格鲁肽主要靶向GLP-1受体，而瑞他鲁肽同时作用于GLP-1、GIP和胰高血糖素受体。这种三重机制旨在产生不同的代谢效应，但临床差异仍需头对头研究确认。
长期心血管结局、停药后维持效果、罕见不良事件和不同人群中的获益风险比尚未完全确定。完整三期数据和监管审评将影响结论。
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.